— Know what they know.
Not Investment Advice

LENZ NASDAQ

LENZ Therapeutics, Inc.
1W: +3.2% 1M: -24.7% 3M: -35.1% YTD: -53.0% 1Y: -73.8%
$7.55
+0.03 (+0.40%)
 
Weekly Expected Move ±13.6%
$5 $6 $7 $8 $9
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 32 · $236.7M mcap · 27M float · 3.44% daily turnover · Short 55% of daily vol

Balance Sheet Trends

Total Assets
$306M +42.1% ▲
5Y CAGR: +68.4%
Total Liabilities
$22M +92.0% ▲
5Y CAGR: -7.8%
Shareholders Equity
$284M +39.3% ▲
Cash & Investments
$292M +39.9% ▲
5Y CAGR: +71.3%
Total Debt
$350K -74.7% ▼
Net Debt
-$25M -32.2% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$18M$44M$35M$20M$25M
Short-Term Investments$0$0$31M$189M$267M
Cash & ST Investments$18M$44M$66M$209M$292M
Net Receivables$0$0$0$0$2M
Inventory$0$0$0$0$0
Other Current Assets$16K$2M$1M$114K-$2M
Total Current Assets$18M$47M$67M$212M$292M
Property, Plant & Equip.$10K$279K$372K$2M$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$2K$31K$3M$1M$14M
Total Non-Current Assets$12K$310K$3M$3M$14M
Total Assets$18M$47M$70M$215M$306M
— Liabilities —
Accounts Payable$460K$5M$6M$4M$4M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$0$17M
Total Current Liabilities$1M$9M$19M$10M$21M
Long-Term Debt$0$0$0$0$350K
Other Non-Current Liab.$31M$61M$144M$0$0
Total Non-Current Liabilities$31M$62M$145M$814K$350K
Total Liabilities$33M$71M$163M$11M$22M
— Equity —
Common Stock$1K$10K$10K$1K$1K
Retained Earnings-$14M-$25M-$95M-$145M-$227M
Accumulated OCI$0$0$6K$196K$242K
Total Stockholders Equity-$14M-$24M-$93M$204M$284M
Total Liabilities & Equity$18M$47M$70M$215M$306M
— Key Metrics —
Total Debt$0$250K$329K$1M$350K
Net Debt-$18M-$44M-$35M-$19M-$25M
Total Investments$0$0$31M$189M$267M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms